Healthy volunteers test new drug ABBV-277 for first time
NCT ID NCT07136103
First seen Sep 30, 2025 · Last updated Jun 16, 2026 · Updated 34 times
Summary
This early-stage study tests a single dose of a new drug called ABBV-277 in 32 healthy adults. The main goal is to check if it is safe, how the body processes it, and whether it triggers an immune response. Participants must be in good general health and have a body mass index between 18 and 32. This study does not aim to treat any disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Acpru /Id# 265681
Grayslake, Illinois, 60030, United States
Conditions
Explore the condition pages connected to this study.